Sagimet Biosciences names Anthony Rimac CFO effective August 1, 2023

Sagimet Biosciences Inc.

Anthony Rimac appointed CFO, principal financial and accounting officer, effective Aug 1, 2023.
Rimac has served as COO since April 2023 and will retain that role.
Board has not yet determined any compensation changes related to CFO appointment.
No family relationships with existing directors/officers; no related party transactions.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Anthony Rimac

Chief Financial Officer, principal financial officer and principal accounting officer

SGMT · Sagimet Biosciences Inc.

Effective: 2023-08-01
Filed: July 27, 2023, 7:59 PM ET

On July 21, 2023, the Board of Directors (the “ Board ”) of Sagimet Biosciences Inc. (the “ Company ”) appointed Anthony Rimac to Chief Financial Officer, principal financial officer and principal accounting officer of the Company to be effective August 1, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Anthony Rimac was appointed as Chief Financial Officer, principal financial officer and principal accounting officer at Sagimet Biosciences Inc..

Action: appointed
Role: Chief Financial Officer, principal financial officer and principal accounting officer

Exact text from the filing

On July 21, 2023, the Board of Directors (the “ Board ”) of Sagimet Biosciences Inc. (the “ Company ”) appointed Anthony Rimac to Chief Financial Officer, principal financial officer and principal accounting officer of the Company to be effective August 1, 2023.

View on SEC.gov

Sagimet Biosciences Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-084764

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.